News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
Double doses of darunavir given with rifampicin lead to high rates of hepatoxicity

Adjusted doses of darunavir/ritonavir (DRV/r) with rifampicin (RIF) were associated with unacceptable risk of hepatotoxicity and a reduction in DRV trough concentrations in a pharmacokinetic (PK) study, conducted in South Africa, presented at CROI 2019.


Published
12 March 2019
From
HIV i-Base
TB transmission and prevention
Co-administration of dolutegravir-based treatment and short course of rifapentine/isoniazid (3HP) well tolerated in people living with HIV

Co-administration of dolutegravir-based antiretroviral therapy and short course (12 weeks) of rifapentine/isoniazid (3HP) for people living with HIV needing preventative treatment for latent tuberculosis (TB) infection was well

Published
12 March 2019
By
Carole Leach-Lemens
HIV treatment for children and young people
Weight Monitoring Key to Pediatric ART Dosing in Resource-Limited Countries

Study findings in a short communication published in HIV Medicine revealed that a large percentage of children living with HIV were prescribed inappropriate doses of antiretroviral therapy (ART) at a pediatric outpatient clinic at Harare Central Hospital in Zimbabwe.

Published
27 February 2019
From
Infectious Disease Advisor
Drug interactions and pharmacokinetics
Potential drug interactions among people with HIV taking statins

Drug interactions remain a potential problem for HIV-positive people who are treated with statins, according to research published in the December issue of the Journal of the American Heart

Published
09 January 2019
By
Michael Carter
Cardiovascular disease
Italian study shows growth in heart and kidney problems in people living with HIV

Reduced kidney function, high blood pressure and cardiovascular disease have each become more common in a large cohort of Italians living with HIV followed since 2004, with

Published
28 December 2018
By
Keith Alcorn
Transgender people
Transgender women taking PrEP have lower levels of PrEP drugs, especially in rectal tissues, than cisgender men

A study presented at last month’s HIV Research for Prevention conference (HIVR4P) in Madrid shows that transgender women who are taking feminising hormones and also taking pre-exposure

Published
09 November 2018
By
Gus Cairns
PrEP science
The long tail of injectable PrEP is especially long for women

Around four in ten women and one in ten men taking injectable cabotegravir as pre-exposure prophylaxis (PrEP) still have evidence of the drug in their body around

Published
25 October 2018
By
Roger Pebody
Cardiovascular disease
Many people take drugs that interfere with their blood pressure pills

People who take pills to lower their blood pressure often take other drugs that reduce the pills’ effectiveness, a recent study suggests.

Published
22 August 2018
From
Reuters
PrEP
PrEP does not lower feminising hormone level in transgender women

Using Truvada (tenofovir DF/emtricitabine) for HIV prevention does not lower levels of feminising hormones, offering reassurance for transgender women who are concerned about drug interactions, according to a

Published
25 July 2018
By
Liz Highleyman
Drug interactions and pharmacokinetics
Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1

New pharmacokinetic data show mean exposure of darunavir (brand name Prezista) boosted with cobicistat (available in combination in Rezolsta, Symtuza) to be lower during the second and third trimesters of pregnancy than during 6–12 weeks postpartum. Low darunavir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child.

Published
18 July 2018
From
MHRA
← Prev12345...24Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.